Market Place
Sourcing Support
Cognito Therapeutics Unveil Spectris Biomarker Data in AD at CTAD
03 Dec 2025 //
BUSINESSWIRE
Cognito Therapeutics Unveils Spectris Biomarker Data at CTAD 2025
18 Nov 2025 //
BUSINESSWIRE
WVU Rockefeller Neuroscience Institute, Cognito Therapeutics
13 Nov 2025 //
BUSINESSWIRE
Cognito Shows Spectris™ Neuroprotective Potential in Alzheimer’s
28 Jul 2025 //
BUSINESSWIRE
Cognito Therapeutics to Present 5 Spectris Abstracts at AAIC 2025
17 Jul 2025 //
BUSINESSWIRE
Cognito Completes Enrollment in HOPE Alzheimer`s Study
01 Jul 2025 //
BUSINESSWIRE
Cognito Therapeutics Delays Alzheimer’s Progression
11 Jun 2025 //
BUSINESSWIRE
Cognito Therapeutics Reveals Spectris™ Data at AD/PD™ 2025
02 Apr 2025 //
BUSINESSWIRE
Cognito Therapeutics Reports Myelin Changes in Alzheimer`s
11 Feb 2025 //
BUSINESSWIRE
Cognito Presents Cost-Effectiveness of Spectris™ for Alzheimer’s
19 Nov 2024 //
BUSINESSWIRE
Cognito Therapeutics’ Spectris™ 56.4% Alzheimer’s Score Reduction
29 Oct 2024 //
BUSINESSWIRE
Cognito Therapeutics To Present Data For Spectris In Alzheimer’s
07 Oct 2024 //
BUSINESSWIRE
Cognito Therapeutics Appoints Christian Howell as Chief Executive Officer
26 Aug 2024 //
BUSINESSWIRE
Cognito`s OVERTURE I Study Shows Significant Time Savings
29 Jul 2024 //
BUSINESSWIRE
Cognito Therapeutics To Present At Alzheimer`s Association Conference 2024
08 Jul 2024 //
BUSINESSWIRE
Cognito: Spectris™ Shows Durable ADL Effects In OVERTURE II
15 Apr 2024 //
BUSINESSWIRE
Cognito Therapeutics Announces Spectris™ OVERTURE OLE Study Data
11 Mar 2024 //
BUSINESSWIRE
Cognito Therapeutics OVERTURE Clinical Trial in Alzheimer`s Disease Published
06 Mar 2024 //
BUSINESSWIRE
Cognito Announces Oral Presentation on Spectris Therapy Open-Label Study Data
28 Feb 2024 //
BUSINESSWIRE
Cognito Therapeutics Announces First Patient Enrolled in HOPE Biomarker Study
23 Jan 2024 //
BUSINESSWIRE
Cognito Therapeutics Phase 2 OVERTURE Study MRI Imaging Analysis Published
11 Dec 2023 //
BUSINESSWIRE
Cognito Therapeutics Appoints Christian Howell as Chief Commercial Officer
30 Oct 2023 //
BUSINESSWIRE
Cognito Therapeutics Presents Phase 2 OVERTURE Study Open-Label Extension Data
24 Oct 2023 //
BUSINESSWIRE
Cognito Therapeutics to Present Phase 2 OVERTURE Study Open-Label Extension Data
18 Oct 2023 //
BUSINESSWIRE
Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer
17 Oct 2023 //
BUSINESSWIRE
Cognito Presents MRI Data Showing Non-Invasive Gamma Stimulation Therapy Reduces Brain Atrophy
17 Jul 2023 //
BUSINESSWIRE
Cognito Announces Presentations at Alzheimer’s Association Conference 2023
26 Jun 2023 //
BUSINESSWIRE
Cognito Therapeutics Announces Poster Presentations at International Society
08 May 2023 //
BUSINESSWIRE
Cognito Announces Key Medical and Technology Leadership Appointments
17 Apr 2023 //
BUSINESSWIRE
Cognito Therapeutics Announces First Patient Enrollment in US Pivotal Study HOPE
21 Feb 2023 //
BUSINESSWIRE
Cognito Therapeutics to Present Data Evaluating Gamma Frequency Neuromodulation
31 Oct 2022 //
BUSINESSWIRE
Cognito Announces Proprietary Gamma Sensory Stimulation for 6 Months
01 Aug 2022 //
BUSINESSWIRE
Cognito’s headset slows brain atrophy in Alzheimer’s study
01 Aug 2022 //
FIERCEBIOTECH
Cognito Therapeutics Announces Data Presentations at the AAIC 2022
13 Jul 2022 //
BUSINESSWIRE
Cognito Therapeutics Joins DiMe Alzheimer`s Disease & Related Dementias Project
09 May 2022 //
BUSINESSWIRE
Cognito Tx, Aetion Announce Partnership to Use AI to Identify Nervous Problems
08 Mar 2022 //
BUSINESSWIRE
Cognito Tx Announces Presentations for Novel Therapeutic in Alzheimer’s Disease
03 Mar 2022 //
BUSINESSWIRE
Cognito Tx to Present Virtual Symposium at 2022 AD/PD Conference
01 Mar 2022 //
BUSINESSWIRE
Cognito Tx Providence Health Launch Phase 3 Study for Disease-Modifying Drugs
27 Jan 2022 //
BUSINESSWIRE
Cognito Therapeutics Announces Formation of Payor Advisory Board
08 Sep 2021 //
BUSINESSWIRE
Cognito to Participate in the BTIG Virtual Biotechnology Conference 2021
04 Aug 2021 //
BUSINESSWIRE
Cognito Therapeutics Announces Upcoming Data Presentations
14 Jul 2021 //
BUSINESS WIRE
Cognito Therapeutics Announces Upcoming Data Presentations
14 Jul 2021 //
BUSINESS WIRE
Cognito Therapeutics initiates Down syndrome Alzheimer’s study
15 Jun 2021 //
PHARMAFILE
Cognito Therapeutics Initiates Studies in Down Syndrome Associated AD
14 Jun 2021 //
BUSINESSWIRE
Cognito`s light-and-sound therapy slows Alzheimer`s declines
09 Mar 2021 //
FIERCE BIOTECH
